FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis Accessibility Statement Skip Navigation EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start "Living with moderate-to-severe atopic dermatitis often means dealing with a cycle of symptoms and time- intensive treatment routines during and in-between flares," said Kristin Belleson ...